Sign inJoin waitlistJoin the waitlist

Alvaro Alencar

Chief Medical Director, SCCC · University of Miami/Jackson Health System

Credentials: · · · · · ·

History

SCCC · University of Miami/Jackson Health System
Present
Sylvester Comprehensive Cancer Center · University of Miami/Jackson Health System
Present
University of Miami/Jackson Health System
Present

Hematology and Medical Oncology
Jackson Memorial Hospital
2005–2008
Internal Medicine
Jackson Memorial Hospital
2002–2005
Doctor of Medicine
1998–2002

Research

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
The Lancet · 2021 · 391 citations
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
New England Journal of Medicine · 2022 · 232 citations
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2023 · 204 citations

Izidore Lossos
11 papers
Juan Alderuccio
9 papers · 3 as a fellow
DT
Donald Tsai
8 papers
Jennifer Brown
8 papers
Lindsey Roeker
7 papers · 1 as a fellow
Nirav Shah
7 papers
Anthony Mato
6 papers
CC
Catherine Coombs
6 papers · 3 as a fellow
Jennifer Woyach
6 papers
Justin Taylor
6 papers
Nicole Lamanna
6 papers
Bita Fakhri
5 papers

Clinical trials

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Principal investigator · Recruiting · Phase 1, Phase 2
Alvaro Alencar, MD
2024–2032
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2021–2027
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032